Overview

Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy (how well the drug works; primarily through the time to relapse) of long-acting injectable paliperidone palmitate compared to treatment as usual with orally administered antipsychotics in monotherapy over 24 months in the treatment of recently diagnosed (1-5 years since diagnosis) schizophrenia.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen-Cilag International NV
Treatments:
Antipsychotic Agents
Paliperidone Palmitate